Pricing Log in Create free account
Friday 6 November 2026 Export NAGE’s income statement to Excel — free account

Niagen Bioscience, Inc.

NAGE Consumer Defensive Packaged Foods

Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024.

Revenue
−20.0%
EPS
−124.7%
Free cash flow
−28.4%

Quarter to September 2026, against a year earlier

2.07 0.04 −1.90%
Market cap
$166.6M
P/E
16.5×
Fwd P/E
20.1×
Dividend yield
—
F-score
6/9
Altman Z
10.54
Beneish M
−1.55
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 34.35%

Capital & Financial Ratios $m

Size
Market Cap 166.56
Revenue ttm 122.29
Net income ttm 10.24
Free cash flow ttm 9.88
Net debt Q (69.51)
Valuation
P/E 16.53
Forward P/E 20.10
Price / sales 1.34
Forward P/S Powerpack
Price / FCF 16.61
Price / book 1.97
Financial health
Current ratio Q 5.93 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (6.10)
Growth
Revenue growth Q −19.99% (below 0%: shrinking)
Operating income growth Q −137.46% (below 0%: shrinking)
EPS, this year −68.35% (below 0%: weak)
EPS, next year A −19.33% (below 0%: weak)
Revenue, next year A +2.92%
EPS, past 5 yrs —
EPS, next 5 yrs A −8.78% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.8×, against a ten-year median of 4.8×; over the ten years it ranged from 0.8× in 2026 to 19.9× in 2017.
P/S against its own 10 years 3.96%
10-year low 10-year high
P/B against its own 10 years 0.04%
10-year low 10-year high
EV/Sales against its own 10 years 0.04%
10-year low 10-year high
EV/FCF against its own 10 years 0.12%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 27 45 65 70
Receivables 5 8 10 7
Inventory 15 9 20 21
Other — — 1 —
50 64 97 100
2023 2024 2025 Q'26
Payables 10 9 11 12
ST’ Debt — — — —
Other 0 1 0 0
21 18 20 17

Compound Annual Growth %

10y 5y 3y
Sales 21.89% 16.91% 21.56%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 30.67% 36.04% 38.72%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.01 Actual −0.01

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.02 0.03 Beat by 0.01
Q1 FY26 0.06 0.07 Beat by 0.01
Q2 FY26 0.01 0.01 Met by 0.00
Q3 FY26 −0.01 −0.01 Met by 0.00
Q4 FY26 −0.02 — Reports 3 March 2027

EPS $

Mar Jun Sep Dec Year
’26 0.07 0.01 (0.01) — —
’25 0.06 0.04 0.05 0.05 0.20
’24 (0.01) 0.00 0.02 0.09 0.11
’23 (0.03) (0.03) (0.01) 0.00 (0.07)
’22 (0.11) (0.09) (0.01) (0.02) (0.24)
’21 (0.12) (0.08) (0.13) (0.08) (0.40)
’20 (0.10) (0.06) (0.07) (0.10) (0.33)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 31 30 27 — —
’25 30 31 34 34 129
’24 22 23 26 29 100
’23 23 20 19 21 84
’22 17 17 17 21 72
’21 15 18 17 18 67
’20 14 15 14 15 59
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 3 3 — —
’25 8 1 4 1 14
’24 0 0 3 9 12
’23 3 3 0 1 7
’22 (7) (4) (4) 0 (15)
’21 (5) (8) (6) (5) (24)
’20 (5) (2) (4) 0 (11)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 5 3 2 — —
’25 8 1 4 1 13
’24 0 0 3 9 12
’23 3 3 0 1 7
’22 (7) (4) (4) 0 (15)
’21 (5) (8) (6) (5) (25)
’20 (5) (2) (4) 0 (11)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 22 21 32 46 59 67 72 84 100 129 122 +22.0% 133 155 172 +9.9%
Gross margin, % 47.96 49.42 50.88 55.67 59.53 61.51 59.40 60.76 61.84 64.28 63.86 +16.3 pt
EBT (4) (17) (33) (32) (20) (27) (17) (5) 9 18 11 n/m
EBT margin, % (16.39) (77.97) (105.57) (69.45) (33.62) (40.22) (22.96) (5.91) 8.89 14.06 9.04 +30.5 pt
Net income (3) (11) (33) (32) (20) (27) (17) (5) 9 17 10 n/m
Per share, $
Per share, $ Revenue 0.58 0.48 0.57 0.81 0.97 1.00 1.03 1.11 1.31 1.63 1.55 +12.2%
Earnings (0.08) (0.26) (0.61) (0.56) (0.33) (0.40) (0.24) (0.07) 0.11 0.22 0.13 n/m
Cash flow (0.08) (0.22) (0.38) (0.36) (0.17) (0.36) (0.22) 0.09 0.16 0.17 0.06 n/m
Capex (0.05) 0.10 (0.03) 0.00 0.00 (0.01) 0.00 0.00 0.00 0.00 0.06 (24.5%)
Free cash flow (0.12) (0.12) (0.41) (0.36) (0.18) (0.37) (0.22) 0.09 0.16 0.17 0.12 n/m
Book value 0.27 1.21 0.49 0.36 0.27 0.47 0.41 0.38 0.61 0.97 1.05 +15.3%
Shares, m 37 45 55 57 61 67 70 75 76 79 79 +8.7%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 51.40 27.65 16.53 7.9
P/S 5.94 13.36 5.98 5.31 4.95 3.73 1.64 1.28 4.05 3.89 1.34 5.0
P/B 12.90 5.26 6.94 12.03 17.85 7.92 4.11 3.77 8.75 6.58 1.97 8.6
EV/Sales 5.97 11.32 5.33 4.95 4.70 3.40 1.38 0.98 3.62 3.40 0.79 4.5
EV/FCF (27.72) (46.13) (7.52) (11.09) (25.91) (9.32) (6.43) 11.76 30.16 33.40 9.75 (5.9)
Cash, $m
Cash, $m Operating cash flow (3) (10) (21) (20) (11) (24) (15) 7 12 14 5 n/m
Capex (2) 5 (1) 0 0 0 0 0 0 0 5 (17.9%)
Free cash flow (5) (5) (22) (21) (11) (25) (15) 7 12 13 10 n/m
Balance, $m
Balance, $m Working capital 7 49 22 18 16 31 29 29 46 77 83 +30.8%
Net debt (1) (45) (22) (19) (17) (24) (20) (27) (45) (65) (70) +54.4%
Shareholders’ equity 10 54 27 20 16 32 29 28 46 77 83 +25.4%
Returns, %
Returns, % ROA (15.21) (27.59) (63.49) (77.95) (50.70) (56.40) (29.56) (9.06) 13.88 19.90 9.90 +35.1 pt
ROIC (20.93) (116.91) (441.21) (1,184.89) 0.00 (220.84) (141.07) (306.16) 336.73 86.63 22.00 +107.6 pt
ROE (38.40) (35.66) (82.25) (135.01) (108.09) (112.68) (54.77) (17.29) 22.94 28.35 13.32 +66.8 pt
People
People Employees 93 74 100 110 110 115 113 106 104 117 — +2.6%
Revenue/emp, $m 0.23 0.29 0.32 0.42 0.54 0.59 0.64 0.79 0.96 1.11 — +18.9%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Niagen Bioscience, Inc. vs peers in Packaged Foods (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PRE Prenetics Global Limited $273.0M — (loss-making) — (loss-making) +288.57% (above 0%: growing) n/m −297.16% (below 0%: shrinking) 64.97% (45.13%) Compare
USNA USANA Health Sciences, Inc. $256.1M — (loss-making) — (loss-making) −3.64% (below 0%: shrinking) n/m +180.61% (above 0%: growing) 76.34% (0.70%) Compare
OTLY Oatly Group AB Sponsored ADR $245.7M — (loss-making) — (loss-making) +9.09% (above 0%: growing) n/m −254.68% (below 0%: shrinking) 34.14% (3.78%) Compare
BRCC BRC Inc. $244.5M — (loss-making) 42.0× +7.27% (above 0%: growing) n/m −141.35% (below 0%: shrinking) 37.14% (6.93%) Compare
BGS B&G Foods, Inc. $200.8M — (loss-making) — (loss-making) −9.70% (below 0%: shrinking) n/m +19.28% (above 0%: growing) 20.78% 9.02% Compare
NATR Nature's Sunshine Products, Inc. $180.5M 13.1× 11.5× −9.14% (below 0%: shrinking) −64.03% (below 0%: shrinking) −45.13% (below 0%: shrinking) 72.86% 4.53% Compare
NAGE Niagen Bioscience, Inc. $166.6M 16.5× 20.1× −19.99% (below 0%: shrinking) n/m −28.44% (below 0%: shrinking) 62.90% (5.84%)
WYHG Wing Yip Food Holdings Group Limited - Sponsored ADR $119.9M — — — — −999.42% (below 0%: shrinking) — — Compare
BYND Beyond Meat, Inc. $110.8M — (loss-making) — (loss-making) −8.17% (below 0%: shrinking) n/m +44.64% (above 0%: growing) 8.53% (44.76%) Compare
Median of peers $222.6M — — −3.64% — −93.24% 37.14% (3.78%)

All 68 Packaged Foods stocks →

Pay and ownership Proxy statement filed 29 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 8.38m 10.28m 132.50
2024 1.21m 2.99m 110.52
2023 1.16m 1.03m 29.79
2022 1.16m 843.38k 35.00
2021 1.10m 2.10m 77.92

Ownership

Directors and executive officers, together 10.00%
Chau Hoi Shuen Solina Holly 24.23%
Robert Fried 5.65%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Niagen Bioscience, Inc. (NAGE) Latest News

5 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · GuruFocus.com

4 Nov

Impact 3 · · Zacks
Impact 3 · · Business Wire

22 Oct

Impact 4 · · Business Wire

20 Oct

Impact 4 · · Business Wire

8 Oct

Impact 3 · · Business Wire

1 Oct

Impact 3 · · Business Wire

30 Sep

Impact 4 · · Business Wire
Impact 3 · · Insider Monkey

21 Sep

Impact 3 · · Business Wire

17 Sep

Impact 3 ·

20 Aug

Impact 4 ·

8 Aug

Impact 4 ·

6 Aug

Impact 4 ·
Impact 3 ·

5 Aug

Impact 4 · transcript

4 Aug

Impact 4 ·

3 Aug

Impact 3 ·

28 Jul

Impact 3 ·

13 Jul

Impact 4 ·

8 Jul

Impact 4 ·

19 Jun

Impact 3 ·

11 May

Impact 4 · · Simply Wall St.

9 May

Impact 4 · · Simply Wall St.

6 May

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 3 · · Zacks
Impact 3 · · Business Wire
stockrow.com/NAGE · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com